CANCER IMMUNOTHERAPY WITH VEGFR-3 TARGETED CAR T-CELLS

Détails

Ressource 1Télécharger: Mémoire no 3405 M. Kiritsis.pdf (2081.72 [Ko])
Etat: Public
Version: Après imprimatur
ID Serval
serval:BIB_AD0E970E95CE
Type
Mémoire
Sous-type
(Mémoire de) maîtrise (master)
Collection
Publications
Institution
Titre
CANCER IMMUNOTHERAPY WITH VEGFR-3 TARGETED CAR T-CELLS
Auteur(s)
KIRITSIS K.
Directeur(s)
COUKOS G.
Codirecteur(s)
IRVING M.
Détails de l'institution
Université de Lausanne, Faculté de biologie et médecine
Statut éditorial
Acceptée
Date de publication
2016
Langue
anglais
Nombre de pages
32
Résumé
Tumorigenesis is the generation and proliferation of cells that have undergone genotypical and phenotypical alterations that
disrupt the physiological balance between proliferation and death. In humans, evidence shows that tumorigenesis is a multistep process, where each step is a genetic mutational event that contributes to the cell tumorigenictraits.1Douglas Hanahan highlighted in his highly cited “Hallmarks of Cancer” (2000) that
mutated cells display six potentials that are shared by most if not all cancer types (Fig 1). Those characteristics, which dictate cancer expansion, include self-sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of programmed cell death (known as apoptosis), limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis.

Mots-clé
Cancer, Immunotherapy, CAR T-cells, Vasculature. VEGFR3
Création de la notice
05/09/2017 13:49
Dernière modification de la notice
20/08/2019 15:17
Données d'usage